openPR Logo
Press release

Learn Details of the Central Nervous System Disorder Drugs Market Report

Learn Details of the Central Nervous System Disorder Drugs

The market for central nervous system disorder drugs comprise of drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson’s disease, Alzheimer’s disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson’s disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. It is reported by Parkinson’s disease Foundation that as of now 7-10 million people are affected with Parkinson’s disease across the globe. These diseases are generally caused by neurodegeneration, autoimmune disorders, trauma, tumors and vascular disorders.

View TOC for this Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1475

The market for CNS disorders is categorized into three segments namely psychiatry, neurology and pain drugs market. Psychiatry drugs market is further segmented into anxiety, depression, bipolar disorders, schizophrenia and ADHD (attention deficit hyperactivity disorder). Neurology drugs market is divided into migraine, epilepsy, Parkinson’s disease, multiple sclerosis, narcolepsy and and Alzheimer’s disease. Pain management drugs market segment comprises of drugs used to treat pain associated with CNS disorders. Among these psychiatry segment holds the largest share accounting for more than 40% followed by neurology and pain segment.

Rapidly increasing geriatric population base resulting in an elevated incidence levels of CNS disorders such as Alzheimer’s disease, Parkinson’s disease, schizophrenia and multiple disorders is one of the key factors driving the growth of the market for CNS disorders.. Currently, there is no drug to cure Alzheimer’s disease, the available medicines only treat the severity of symptoms and improve the quality of life to some extent. That is why companies such as Eli Lilly, Baxter International and Novartis AG are investing heavily in research and development in order to accelerate the treatment of Alzheimer’s disease.

Geographically, North America holds the largest share of the total market of CNS disorders followed by Europe and Asia-Pacific. Asia-Pacific is projected to grow at a CAGR more than other regions on account of high prevalence of diseases such as epilepsy, Parkinson’s disease and Alzheimer’s disease. As of 2012, WHO (world health organization) suggests that around 50 million people are suffering from epilepsy worldwide, most of them (approximately 80%) belong to developing nations.

Fill the form to gain deeper insights on this market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1475

Some of the key players operating in the market for CNS disorders are Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis AG, Sanofi, Merck & Co., Abbott Laboratories, Eli Lilly, UCB, Bristol-Meyers Squibb Co. and Astellas Pharma, Inc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Learn Details of the Central Nervous System Disorder Drugs Market Report here

News-ID: 785759 • Views:

More Releases from Transparency Market Research

Global Avocado-based Products Industry Valued at USD 2.5 Billion in 2024; Projected to Reach USD 5.4 Billion by 2035, Expanding at a CAGR of 6.2%
Global Avocado-based Products Industry Valued at USD 2.5 Billion in 2024; Projec …
The global avocado-based products market(https://www.transparencymarketresearch.com/avocado-based-products-market.html) is gaining strong traction owing to increasing consumer awareness about the health benefits of plant-based and natural foods, coupled with significant advancements in food processing technologies. As per industry estimates, the market was valued at US$ 2.5 Bn in 2024 and is projected to grow at a CAGR of 6.2% from 2025 to 2035, to cross US$ 5.4 Bn by the end of 2035. Discover Market
Warehouse Robotics Market Size to Surpass USD 61.8 Billion by 2035 | Growth Fueled by AI, Vision Systems, and Contactless Automation Across Global E-Commerce and Supply Chains
Warehouse Robotics Market Size to Surpass USD 61.8 Billion by 2035 | Growth Fuel …
The global warehouse robotics market (https://www.transparencymarketresearch.com/warehouse-robotics-market.html) is entering a transformative decade, fueled by the accelerating adoption of automation technologies across logistics, retail, and manufacturing sectors. Valued at US$ 11.6 billion in 2024, the market is projected to grow at a CAGR of 13.8% between 2025 and 2035, reaching a staggering US$ 61.8 billion by 2035. This remarkable growth is driven by rising e-commerce activities, labor shortages, advancements in artificial intelligence (AI),
Global Manufacturing Execution System (MES) Market to Surpass US$ 51.2 Bn by 2035 | Transparency Market Research
Global Manufacturing Execution System (MES) Market to Surpass US$ 51.2 Bn by 203 …
The global Manufacturing Execution System (MES) market is set to experience robust expansion in the coming decade, reflecting the ongoing digital transformation across industries. Valued at US$ 16.9 billion in 2024, the MES market is projected to grow at a CAGR of 10.6% from 2025 to 2035, reaching approximately US$ 51.2 billion by 2035, according to the latest industry analysis. Manufacturing Execution Systems (MES) are increasingly becoming the digital backbone of
HVAC Chillers Market Outlook 2035: Energy-Efficient Cooling Systems Driving Steady 5% CAGR Growth | TMR
HVAC Chillers Market Outlook 2035: Energy-Efficient Cooling Systems Driving Stea …
The global HVAC chillers market is on a robust growth trajectory, powered by the world's increasing emphasis on energy efficiency, sustainability, and the modernization of infrastructure. According to recent market intelligence, the HVAC chillers industry, valued at US$ 13.5 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 5.0% between 2025 and 2035, reaching approximately US$ 23.2 billion by the end of 2035. This upward

All 5 Releases


More Releases for Parkinson’s

Parkinson’s Disease Treatment Market 2021 | Detailed Report
Parkinson’s Disease Treatment Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Parkinsons Disease Treatment Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5024082 The report provides a comprehensive analysis of company profiles listed below: - Teva - Roche - Prothena - Acorda
Parkinson’s Disease Treatment Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Parkinson’s Disease Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Parkinson’s Disease Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Parkinson’s Disease Treatment with respect
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent. Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial